Minka Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
Paris, France
Type:
sample
Technology:
sample
sample
sample
sample
About: Following several months of strategic review and heavy financial restructuring, Innavirvax is reborn as Minka Therapeutics with a new sense of purpose and stronger ambitions.
With positive phase II data in hands for its HIV vaccine, the company has demonstrated the potential value of its 3S/p44L technology platform.
The expertise gained in NK cells involvement in HIV disease will be more specifically leveraged to develop new therapeutics in key commercial indications in infectious diseases and in oncology.
Minka Therapeutics intends to strengthen its core technology base beyond vaccines and will be announcing key strategic collaborations with leading academic institutions in the coming months.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Minka Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.